Power3 Buys Rozetta-Cell | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Power3 Medical Products today announced a definitive agreement to acquire all the stock of stem cell firm Rozetta-Cell Life Sciences.

Upon completion of the deal, expected in October or November, Rozetta-Cell will be merged with Power3 and take its name.

Terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.